A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i

Administered By

Contributors

Start/End

  • May 14, 2018 - May 31, 2023